India’s most recent tryst with pharmaceutical product patents is eleven years old. These years have seen a number of …) Undertakings for non-commercialisation given by generic companies also act/stand on same footing as injunctions; and e) India will …

snapshot of the biotech industry in India today. It will serve as a baseline for the scenario in future. (Article freely …

adopted by India might be in violation of the non discrimination principle enshrined in Article 27(1) TRIPS Agreement …

. The problem started when the Chennai HC approved the Govt. of India’s decision not to grant patent to Gleevec. Novartis … appealed in the Supreme Court of India, and the case has been winding through for the last six years and now the Court is … gastrointestinal cancer. India is the world’s third-largest drug producer by volume and exports about $10 billion worth of generic …

regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent … ; India …

affect India's pharmaceutical industry, Fink simulates the effects of introducing such protection - as required by the World … welfare. (India must amend its current patent regime by 2005 and establish a transitional regime in the meanwhile.) The model … groups, a subset of all available drugs was patent-protected in Western Europe but not India, where Indian manufacturers …

To address questions about how stronger patent rights will affect India's pharmaceutical industry, the author simulates …-Related Intellectual Property Rights (TRIPs) - on market structure and static consumer welfare. (India must amend its current patent regime …-protected in Western Europe but no India, where Indian manufacturers freely imitated them. The simulation analysis asks how the …